Basal cell carcinoma
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Zilonda zowopsa zomwe zimakhudza khungu la mphuno mwa munthu wokalamba nthawi zambiri zimapezeka ngati Basal cell carcinoma. Mphuno ndi malo omwe amapezeka pamtundu wotere wa khansa yapakhungu.
Basal cell carcinoma ikhoza kukhala ndi malire ndi zilonda zosakhazikika.
Basal cell carcinoma zitha kuganiziridwa kuti ndi njerewere.
References
Basal cell carcinoma (BCC) ndi mtundu wofala kwambiri wa khansa yapakhungu. Kuwala kwadzuwa ndiko chifukwa chachikulu. Pafupifupi milandu yonse ya BCC imawonetsa kusanja kwa Hedgehog pakuwunika kwa maselo. Mankhwala osiyanasiyana amapezeka ndikusankhidwa malinga ndi chiopsezo chobwereranso, kufunika kwa kusunga minofu, zokonda za odwala, ndi kukula kwa matenda.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas ndi mtundu wofala kwambiri wa khansa yapakhungu mwa akulu akhungu loyera azaka zapakati pa 50 ndi kupitilira apo. Chiwerengero chawo chikukwera padziko lonse lapansi, makamaka chifukwa cha kuwala kwa dzuwa. Mitundu ina ya majini imatha kupangitsa anthu kukhala ndi chizolowezi chopanga khansa iyi ali achichepere. Basal cell carcinomas zimasiyanasiyana kuuma kwake, kuyambira ku zotupa zapakhungu zomwe zimatha kuchira mosavuta mpaka zokulirapo zomwe zimafunikira kukambirana m'magulu apadera azachipatala. Kudziwiratu kumadalira kuthekera kwa khansara kubwerera kapena kutha kwake kuwononga minofu yapafupi. Opaleshoni ndiye chithandizo chokhazikika nthawi zambiri, kuonetsetsa kuti achotsedwa bwino komanso mwayi wochepa wobwereza. Njira zocheperako zimatha kuchiza zilonda zam'mwamba.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Chithandizo choyambirira cha BCC ndi opaleshoni. Kwa BCC yowopsa kapena yobwerezabwereza, makamaka m'madera ovuta, opaleshoni yoyendetsedwa ndi micrographically ikulimbikitsidwa. Odwala omwe ali ndi chiwopsezo chochepa cha BCC amatha kuganizira zachipatala kapena njira zowononga. Thandizo la Photodynamic limagwira bwino pa ma BCC owoneka bwino komanso opanda chiopsezo chochepa. Kwa BCC yapamwamba kapena metastatic, Hedgehog inhibitors (vismodegib, sonidegib) amalimbikitsidwa. Ngati pali kukwera kwa matenda kapena kusalolera kwa Hedgehog inhibitors, immunotherapy ndi anti-PD1 antibody (cemiplimab) ingaganizidwe. Radiotherapy ndi njira yabwino kwa odwala omwe sangathe kuchitidwa opaleshoni, makamaka odwala okalamba. Electrochemotherapy ikhoza kuganiziridwa ngati opaleshoni kapena radiotherapy sichotheka.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Zinthu zowopsa zimaphatikizapo kukhudzidwa ndi kuwala kwa ultraviolet, chithandizo cha radiation, kuwonetsa kwanthawi yayitali ku arsenic komanso kusagwira bwino ntchito kwa chitetezo chamthupi (monga kupatsirana chiwalo). Kuyatsa kwa UV paubwana ndikovulaza kwambiri.
Pambuyo pozindikira ndi biopsy, chithandizo chimakhala ndi kuchotsa opaleshoni. Izi zitha kukhala mwa kudula kosavuta ngati khansara ndi yaying'ono; Ngati khansayo si yaying'ono, opaleshoni ya Mohs nthawi zambiri imalimbikitsidwa.
Basal cell carcinoma imatenga pafupifupi 32% ya khansa zonse padziko lonse lapansi. Pa khansa yapakhungu kupatulapo khansa yapakhungu, pafupifupi 80 peresenti ndi khansa ya basal-cell. Ku United States, pafupifupi 35 peresenti ya amuna oyera ndi 25 peresenti ya akazi oyera amakhudzidwa ndi basal cell carcinoma panthawi ina ya moyo wawo.
○ Kuzindikira ndi Chithandizo
#Dermoscopy
#Skin biopsy
#Mohs surgery